Non–Cystic Fibrosis Bronchiectasis

McShane, Pamela J.; Naureckas, Edward T.; Tino, Gregory; Strek, Mary E.

doi:10.1164/rccm.201303-0411ci

Cited by 338 publications

(322 citation statements)

References 104 publications

Supporting

Mentioning

292

Contrasting

Unclassified

Order By: Relevance

“…The rate of congenital malformations in BE etiology differs between 1% and 13.6% [14][15][16][17][18][19][20] . 1.8% of our cases had congenital malformations (one pulmonary sequestration and one idiopathic congenital BE) (Table I).…”

Section: Discussionmentioning

confidence: 99%

Changing epidemiology of non-cystic fibrosis bronchiectasis

Bahçeci¹,

Karaman²,

Nacaroğlu³

et al. 2016

Turk J Pediatr

View full text Add to dashboard Cite

The etiology of bronchiectasis was detected as; primary ciliary dyskinesia 26.4%, protracted bacterial bronchitis 22.8%, primary immune deficiency 11.8%, bronchiolitis obliterans 8.2%, lung disease secondary to gastro-esophageal reflux 3.7%, foreign body aspiration 2.7%, tuberculosis %2.7, congenital malformation 1.8% and asthma 1.8%, respectively. In 15.4% of cases, etiology was not identified clearly. 91% of the patients were medically treated.In ten years, the frequency of asthma and tuberculosis in etiology had decreased but primary ciliary dyskinesia and primary immune deficiency had increased. Non-cystic fibrosis bronchiectasis can be followed up for a long time with medical treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Changing epidemiology of non-cystic fibrosis bronchiectasis

Bahçeci¹,

Karaman²,

Nacaroğlu³

et al. 2016

Turk J Pediatr

View full text Add to dashboard Cite

show abstract

“…However, pulmonary spirometry and radiological interpretation are insufficient to capture the complexity of this disease (5) as patients with similar prognoses may have variable pulmonary spirometry and radiological findings. At present, there is no simple parameter to accurately evaluate the prognosis of non-CF bronchiectasis.…”

Section: Introductionmentioning

confidence: 99%

Distance-saturation product of the 6-minute walk test predicts mortality of patients with non-cystic fibrosis bronchiectasis

et al. 2017

View full text Add to dashboard Cite

Background: Previous surveillance methods to monitor the prognoses of patients with bronchiectasis are too complex for use in daily practice. The 6-minute walk test (6MWT) is a simple exercise test to predict the prognosis of chronic obstructive airway disease and numerous chronic lung diseases, including idiopathic pulmonary fibrosis. No studies have investigated exercise-induced oxygen desaturation (EID) and distancesaturation product (DSP) of 6MWT to predict the prognoses of patients with bronchiectasis. Methods: This was a prospective study to identify correlations between variables of 6MWT and mortality in patients with bronchiectasis over a 6-year period. The study cohort included 69 patients with stable noncystic fibrosis (non-CF) bronchiectasis who were regularly evaluated for functional status via 6-minute walk distance (6MWD), spirometry, BODE index, EID, and DSP.Results: Of the 69 patients, 9 (13%) died and 60 (87%) survived during the 6-year follow-up period. Multivariate analysis showed that DSP (OR =0.983; P=0.001) was the best parameter of 6MWT to predict mortality. Patients with a lower DSP of <280 m% were at a 66.5-fold greater risk (OR =66.5; 95% CI: 9.4-469.2) of 6-year mortality compared with those with DSP >280 m% (P<0.001).Conclusions: DSP is a simple parameter to predict 6-year mortality in patients with non-CF bronchiectasis.

show abstract

“…They are often applied in reference to the radiological appearance of disease. Radiological appearance is likely to be insufficient to capture the complexity of disease impact in bronchiectasis (4).…”

mentioning

confidence: 99%

The Bronchiectasis Severity Index. An International Derivation and Validation Study

Chalmers

Goeminne²,

Aliberti

et al. 2014

Am J Respir Crit Care Med

813

836

View full text Add to dashboard Cite

Rationale: There are no risk stratification tools for morbidity and mortality in bronchiectasis. Identifying patients at risk of exacerbations, hospital admissions, and mortality is vital for future research.Objectives: This study describes the derivation and validation of the Bronchiectasis Severity Index (BSI).Methods: Derivation of the BSI used data from a prospective cohort study (Edinburgh, UK, 2008 enrolling 608 patients. Cox proportional hazard regression was used to identify independent predictors of mortality and hospitalization over 4-year follow-up. The score was validated in independent cohorts from Dundee, UK (n = 218); Leuven, Belgium (n = 253); Monza, Italy (n = 105); and Newcastle, UK (n = 126).Measurements and Main Results: Independent predictors of future hospitalization were prior hospital admissions, Medical Research Council dyspnea score greater than or equal to 4, FEV 1 , 30% predicted, Pseudomonas aeruginosa colonization, colonization with other pathogenic organisms, and three or more lobes involved on high-resolution computed tomography. Independent predictors of mortality were older age, low FEV 1 , lower body mass index, prior hospitalization, and three or more exacerbations in the year before the study. The derived BSI predicted mortality and hospitalization: area under the receiver operator characteristic curve (AUC) 0.80 (95% confidence interval, 0.74-0.86) for mortality and AUC 0.88 (95% confidence interval, 0.84-0.91) for hospitalization, respectively.There was a clear difference in exacerbation frequency and quality of life using the St. George's Respiratory Questionnaire between patients classified as low, intermediate, and high risk by the score (P , 0.0001 for all comparisons). In the validation cohorts, the AUC for mortality ranged from 0.81 to 0.84 and for hospitalization from 0.80 to 0.88. Conclusions:The BSI is a useful clinical predictive tool that identifies patients at risk of future mortality, hospitalization, and exacerbations across healthcare systems.

show abstract

Non–Cystic Fibrosis Bronchiectasis

Cited by 338 publications

References 104 publications

Changing epidemiology of non-cystic fibrosis bronchiectasis

Changing epidemiology of non-cystic fibrosis bronchiectasis

Distance-saturation product of the 6-minute walk test predicts mortality of patients with non-cystic fibrosis bronchiectasis

The Bronchiectasis Severity Index. An International Derivation and Validation Study

Contact Info

Product

Resources

About